Company intelligence / Profile preview

Teijin

Ownership: Public · 3401
Employees: ~20279
Development stage: Commercial

Overview

Teijin has several approved drugs in Japan and internationally for indications such as type 2 diabetes mellitus ("alogliptin benzoate"), asthma ("ciclesonide"), osteoporosis ("Onealfa", "tacalcitol hydrate"), xerostomia ("sodium chloride/potassium chloride/calcium chloride hydrate/magnesium chloride/dipotassium phosphate"), psoriasis ("tacalcitol hydrate") and constipation ("sodium picosulfate hydrate"). The company submitted an application in December 2024 for palopegteriparatide for hypoparathyroidism.

Therapeutic areas: GastroenterologyPulmonologyCardiovascularRheumatologyDermatology
Modalities: Small moleculeMonoclonal antibodyEnzyme replacement therapySynthetic peptide
Industry: Biotech

Drug pipeline

1 asset

TEI-W00595

Unknown

Partnerships

Ascendis Pharma A/S for palopegteriparatide development/submission in Japan.

Beyond the preview

Go deeper on Teijin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Teijin.

Explore the full profile